Psychedelics and ketamine as plasticity openers, not magic cures

The Short Version

Ketamine blocks NMDA receptors, psilocybin activates serotonin 2A receptors, and MDMA floods the brain with serotonin and dopamine and acts largely through serotonin 1B receptors. Yet across six Huberman Lab conversations, each is described the same way: as something that starts a process of brain change, not as the change itself [1][3][4]. Andrew Huberman calls psychedelics "a wedge" under "the boulder that is the neuroplasticity" [3], and describes the drug experience as a "wavefront that sets off processes lasting hours, weeks or months [1]. Whether that plasticity helps depends on what happens next: therapy, integration, antidepressive behaviors and ongoing practice. That is why ketamine's relief fades in days without repeated sessions [1], why relapse after psilocybin for treatment-resistant depression is more the rule than the exception by three months [2], and why MDMA taken on its own does not cure PTSD" [4]. Neuralink neurosurgeon Matthew MacDougall goes further, arguing that because plasticity means changing about a trillion synapses across the whole brain, drugs rather than electrodes are the most promising tool for boosting it in adults [6].

Table of contents

What They Said

Andrew Huberman on ketamine: a plasticity blocker that creates plasticity

Huberman's solo episode on ketamine is the most detailed account in the sources of how a drug can open up the brain to change, and why the opening alone is not enough [1]. He starts with a puzzle. In the early 1990s, labs using the learned helplessness model of depression found that rats and mice given sub-anesthetic ketamine kept swimming much longer before giving up [1]. That made no obvious sense, because ketamine is an NMDA receptor antagonist, and NMDA receptors are critical for neuroplasticity, which should be needed to recover from depression [1]. In his words: "This is a drug that blocks neuroplasticity but somehow is relieving depression" [1]. Some scientists would walk away from that; others say "I like a good puzzle" and dig in, and thanks to them clinicians began trying ketamine in depressed patients around 2000 [1].

The first landmark study gave seven people with major depression intravenous ketamine at half a milligram per kilogram of body weight [1]. Effects began within 10 to 15 minutes, a dreamy, semi-dissociative state peaked around 45 minutes to an hour and was over by about two hours, and relief from depression came almost immediately and lasted at least three days [1]. Later studies extended its use to suicidality, treatment-resistant depression, bipolar depression, PTSD, OCD, anxiety and some addictions [1].

But Huberman refuses to call it a miracle: "I don't actually believe in miracle drugs. I don't think that there is any compound that alone can produce all the desired effects that one wants without any negative effects in a way that could warrant calling it a miracle drug" [1]. The antidepressant effect usually wears off after about three days to a week [1]. Clinical regimens such as twice a week for three weeks give relief throughout, and afterwards "people often will experience weeks or months of relief from depression when they're not doing the weekly ketamine therapy sessions" [1]. He attributes that durability to rewiring: "that longer-term relief that I'm referring to as durability of the treatment is very likely to be the consequence of actual neural circuit rewiring" [1].

The mechanism he lays out runs like this. NMDA receptors act as an "AND gate, switching on only with unusual or intense patterns of activity, and they trigger gene expression and the insertion of more AMPA receptors so that a repeated behavior becomes easier [1]. Ketamine binds NMDA receptors on inhibitory neurons, releasing the brake on excitatory neurons in mood circuits, which then fire in bursts, the ideal pattern for inducing plasticity [1]. It blocks the receptor that everyone thinks is involved in neuroplasticity. And in doing so, it actually creates neuroplasticity" [1]. That burst firing releases BDNF, which binds TrkB receptors, inserts new glutamate receptors and can make neurons grow new branches [1]. The evidence that BDNF matters is threefold: in BDNF knockout mice ketamine no longer makes them swim longer; depressed people with a poorly functioning form of BDNF respond much less to ketamine; and ketamine itself may bind TrkB and mimic BDNF [1]. Huberman finds exciting the model of ketamine acting more or less like a growth factor that lets mood circuits change and makes the changes durable [1].

Crucially, he emphasizes that this rewiring is slow. "What I just described to you as a process that actually occurs in the brain takes many, many days. It involves cells changing gene expression, making new proteins, new receptors" [1]. Even so-called short-term plasticity is "happening over the course of at least many, many hours and more likely many days or even weeks" [1]. The two-hour trip is over long before the rewiring is done.

He then adds the opioid twist. A study from his Stanford colleagues Nolan Williams, Alan Schatzberg and colleagues gave patients naltrexone to block opioid receptors along with ketamine; they still felt the euphoria and dissociation, but lost the antidepressant effect [1]. From this he draws a lesson that he applies explicitly to ketamine, psilocybin and MDMA alike: "Those immediate effects may not actually be related to the long-term clinical benefit of those particular drugs" [1]. People "collapse those two things and presume that their experience of what they saw, what they heard, how they felt while they were under the influence of the drug, was actually the stimulus that created the relief" [1]. He is careful not to overcorrect: "I don't think it's going to be an either or situation" [1]. Instead he views the experience as "a sort of wavefront" that "sets off a series and in fact multiple series" of processes, some relying on NMDA and BDNF plasticity, others on the opioid pathway, "and that each of these have different time courses such that some provide immediate relief in the days and hours after treatment, some in the weeks after treatment and some more durable long-lasting changes that can occur over months or maybe even years" [1].

Then comes the point that makes ketamine a window rather than a cure. The circuits involved, the habenula (a disappointment circuit), the mesolimbic reward pathway and its links with the frontal cortex, which handles context-dependent strategy, are not designed to respond to ketamine; they are designed to respond to thinking and behavior [1]. A drug only biases the probability that circuits will be engaged [1]. Someone who takes ketamine but keeps up pro-depressive behaviors will likely get little relief, while someone who pursues stimulating work, social connection and care for their body will reinforce the changes [1]. Huberman notes that people who get relief "are going back to work. They are engaging in relationships again. They are viewing them self differently again," and that "it is impossible to separate the positive behavioral consequences of a drug treatment for depression from the drug itself" [1]. He closes with a colleague's line: "better living through chemistry still requires better living" [1].

Supporting evidence that NMDA blockade alone is not the whole story: memantine, an NMDA blocker used for Alzheimer's disease, has no antidepressant effect [1].

Andrew Huberman on psilocybin: "a wedge" under the boulder

In his psilocybin episode, Huberman describes a different chemistry reaching a similar place [3]. Psilocybin is converted in the gut to psilocin, which closely resembles serotonin but strongly and selectively activates the serotonin 2A receptor [3]. He contrasts this with SSRIs, which spray extra serotonin non-specifically across many receptors [3]. Serotonin 2A receptors sit densely on the apical dendrites of cortical pyramidal neurons, including in the prefrontal and visual cortex; activating them increases lateral communication, making the brain less modular and less hierarchical, with thalamic gating broadening so senses blend [3].

The lasting change he describes is structural. A study in Neuron found that psilocybin induces rapid and persistent growth of dendritic spines in the frontal cortex of mice, and depressed patients show fewer spines in frontal cortex neurons in postmortem tissue, with effective treatments correlating with spine growth [3]. He adds caveats: the mouse studies used about 1 milligram per kilogram, roughly double or triple human therapeutic doses, and multiple mechanisms likely act in parallel, including pruning of unhelpful connections [3]. Neurogenesis, he says, is not how psilocybin works [3]. A study from Carhart-Harris's lab found increased connectivity between resting-state networks even after psilocybin and MDMA wore off [3], and a music study found rewired connections between emotion centers, including the ventral tegmental area and reward pathways, and auditory networks, so people with depression could enjoy music again, with changes lasting well beyond the session [3].

His central analogy is the clearest statement in the sources of the insight's point: "Think about them as a wedge that gets underneath the boulder that is the neuroplasticity that gets rolling forward And then think about whether or not the plasticity is adaptive or maladaptive whether or not it actually serves you in your life on a daily basis" [3]. The direction depends "on whether or not you're using your conscious brain to move that boulder in a particular direction Not just bulldozing through things and destroying them, but clearing a path through old ineffective maybe even destructive patterns of thoughts or emotions" [3]. He offers this image deliberately to correct "the typical Discussion around psychedelics that we tend to hear which is that oh it creates plasticity and plasticity is what you want" [3]. Rewiring alone is not the goal, he stresses, since brain injury and methamphetamine also rewire the brain, maladaptively [3].

He also stresses that the setting shapes what the plasticity does. Researchers he has spoken to consider an eye mask or closed eyes a very if not the critical feature of a therapeutic journey, because going inward lets people combine imagery with thoughts, memories and emotions, which appears to drive lasting benefit; that is the difference between a clinical journey and taking mushrooms and heading to the woods or the beach [3]. Clinical sessions use carefully arced music, trained guides and supportive therapy [3]. Across about a dozen strong trials, typically two 25-milligram sessions about a week apart with supportive therapy, roughly 60 to 75% of people with major depressive disorder experience substantial relief [3]. One trial he paraphrases reported effect sizes about 2.5 times greater than psychotherapy studies and more than four times greater than antidepressant drug studies, with about 11 hours of psychotherapy alongside the sessions, consistent with evidence that combining drug and talk therapy beats either alone [3].

Andrew Huberman on MDMA: a tool that augments talk therapy

MDMA works through a third route [4]. Like methamphetamine, it blocks dopamine transporters and causes massive dopamine release, but it does the same for serotonin, with serotonin increases at least three and perhaps as much as eight times greater than the dopamine increases [4]. Its pro-social effects come largely from serotonin acting on 1B receptors in the nucleus accumbens, while dopamine drives its rewarding quality, according to a mouse study from Robert Malenka's lab at Stanford [4]. Huberman separates it from classic psychedelics (serotonin 2A) and from ketamine (an NMDA blocker) and expects it will stop being called a psychedelic [4]. MDMA strongly rewards social connection itself, making connection more likely even after the drug wears off [4].

Its brain-level effects are different, too. People on MDMA rate threatening faces as less threatening, with reduced amygdala activity [4]. PTSD is associated with heightened connectivity between the amygdala and the insula, and in people given MDMA alongside therapy that connectivity weakens, with the degree of weakening scaling with symptom relief [4]. Unlike psilocybin, MDMA does not seem to produce lasting increases in lateral connectivity across the cortex [4].

Yet the framing is the same. Huberman draws on psychiatrist Paul Conti's definition that "trauma is an event that fundamentally changes the way that our brain works for the worse," and explains that under MDMA people are more willing to trust both their therapist and themselves to explore such events [4]. He repeats: "MDMA taken on its own does not cure PTSD" [4]. It augments talk therapy [4]. The MAPS phase 3 protocol makes the point structurally: three 90-minute preparatory sessions with two therapists, then three roughly eight-hour sessions with MDMA or placebo, then three 90-minute integration sessions spaced a week apart [4]. The result was an 88 percent clinically effective response rate with MDMA-assisted therapy versus 60 percent with therapy and placebo, and 67 percent of the MDMA group no longer met criteria for PTSD by the end of treatment [4]. Notably, the placebo group received the same therapy and still did well, which shows how much the therapy itself carries [4]. His bigger takeaway is that MDMA, like other compounds now being studied, is ultimately a tool for accessing neuroplasticity, helping the brain rewire in adaptive ways when used safely and in the right therapeutic context [4].

Huberman in Sydney: feeling and reflecting at the same time

At his Sydney Opera House Q&A, Huberman describes from the inside why drug and therapy work together [5]. He took part in both a psilocybin trial and an MDMA trial as an adult, found them "absolutely terrifying" at times, "but I learned a lot and there does seem to be an antidepressant effect" [5]. As someone who has done "an immense amount of therapy," he values insight-oriented talk therapy, but "it's hard to experience the fullness of that issue in that moment while also parsing it cognitively" [5]. Psychedelics "and to some extent MDMA allow people to get into the full amplitude maybe even enhanced amplitude emotionality of an experience and at the same time allow people to reflect and with the help of a so-called guide or the therapist take notes in a way that lead to specific actionable outcomes" [5]. In his summary: "you can get real time experience with insight and of course you need support as well" [5]. He explains psilocybin "seems to create more what we call resting state lateral connectivity" after the journey [5], and that MDMA's therapeutic effect seems to come mostly from its serotonergic action [5]. Here the drug provides the emotional access; the guide, the notes and the actions afterward turn it into change.

Robin Carhart-Harris: the experience matters, and integration is lifelong

Dr. Robin Carhart-Harris, distinguished professor of neurology and psychiatry at UCSF, supplies the imaging evidence that psilocybin opens up the brain, and the most candid account of what happens when the opening closes [2]. Under psilocybin, communication spreads across brain modules that normally talk mostly to themselves, which his team calls increased global functional connectivity, and the effect tracks how intense the experience is; computational models suggest the serotonin 2A receptor drives this [2]. Crucially, it persists: in two depression cohorts, his team saw reduced modularity the day after psilocybin therapy and again three weeks later, and the size of that change correlated with how much symptoms improved [2]. He describes depression as a hollow in a landscape, easy to fall into and hard to climb out of, with the bias that nothing will ever change, and suggests opening up the brain may relate to opening up the mind [2].

In an unpublished study of healthy first-time users, only the 25-milligram dose (not a 1-milligram placebo-like dose) produced changes: improved well-being, an entropic brain effect on EEG where activity becomes more complex and less predictable, better cognitive flexibility, and decreased axial diffusivity in two major tracts connecting the prefrontal cortex with the thalamus and striatum, which may mean stronger tract integrity [2]. He stresses that it is one study, the anatomical change did not correlate with psychological outcomes, and its functional meaning is unknown [2].

Where he differs in emphasis from Huberman's ketamine episode is on the experience itself. He says the evidence that the experience drives healing is not a hunch: independent teams keep finding that the strength of certain experiences reliably predicts outcomes [2]. He writes psychedelic-therapy with a hyphen, as a combination treatment whose parts likely work together [2]. The guiding mantra, which he attributes to Bill Richards, is "trust, let go be open" [2]. Trust in the therapists, measured by a single rating on the morning of dosing, significantly predicts both the quality of the experience and outcomes weeks or months later, and letting go also predicts response [2]. He is skeptical of efforts to build drugs that act on the same receptors without any trip, finding the logic unconvincing and suspecting wishful thinking [2]. And in the psilocybin versus escitalopram trial, expectancy predicted improvement with escitalopram on nearly every measure but with psilocybin on none of roughly a dozen scales, which he sees as a serious blow to the idea that psychedelic therapy is just a super-placebo [2]. He also distinguishes "psychedelic therapy versus taking a psychedelic": "you shut your eyes," and "it's a world away from taking a psychedelic, yeah, a rave or something" [2].

On what happens afterward, he is blunt. Asked how long integration lasts, he quotes Jack Kornfield: "after the ecstasy, the laundry" [2]. Psychedelics give people a leg up to do very difficult work, but the work is lifelong; since clinics cannot support patients forever, integration eventually becomes a practice, like meditation [2]. He quotes a former colleague's line: "psychedelic therapy allows you to sit with rather than sit on" difficult feelings, in contrast to daily medication [2]. And he admits the paradox: the ego can return, sometimes with a vengeance, and in treatment-resistant depression relapse by three months is more the rule than the exception [2]. Some early patients remain well years later, but most would need more sessions, which the law forbids once a trial ends [2].

On MDMA he says psilocybin can reach the core of suffering reliably but sometimes aggressively, triggering defenses in people with PTSD, while MDMA makes it easier and safer to revisit trauma, though perhaps not as deeply [2].

Matthew MacDougall: drugs, not electrodes

The most surprising voice comes from Neuralink's head neurosurgeon [6]. Asked about adult neuroplasticity, MacDougall says plasticity declines with age, and he thinks drugs, including the psychedelics Huberman mentions, will be more fruitful than implants for boosting it [6]. His reason is scale: changing plasticity means altering something like a trillion synapses across the whole brain, which a drug can reach and an electrode cannot [6]. Even steerable electrodes will never, in his view, cover the brain the way a drug does within our lifetimes [6]. Neuralink is not currently combining drugs with stimulation, because decoding the brain electrically is hard enough [6]. Current implants reach only the brain's surface, so deep functions like mood, addiction and sleep will come later [6]. His longer-term hope, over 10 to 20 years, is to give people control over the ways the brain goes wrong, such as addiction and depression [6]. From a builder of the most advanced brain hardware, this is a striking endorsement of chemistry as today's broadest plasticity lever.

Where They Agree, and Where They Don't

They agree that each drug works through a different receptor. Ketamine blocks NMDA receptors (and binds opioid receptors) [1]; psilocybin selectively activates serotonin 2A [3][2]; MDMA releases serotonin and dopamine and acts largely through serotonin 1B [4]. Huberman explicitly separates the three in his MDMA episode [4], and contrasts ketamine's convoluted route with psilocybin's more straightforward serotonin receptor mechanism [1].

They agree that each starts rewiring rather than finishing it. Ketamine's plasticity "takes many, many days" [1]; psilocybin is "a wedge" [3]; MDMA is ultimately a tool for accessing neuroplasticity [4]; psychedelics give a leg up to lifelong work [2]. And every clinical protocol described pairs the drug with human support: preparation and integration sessions for MDMA [4], two therapists, music and eye masks for psilocybin [2][3], and antidepressive behaviors for ketamine [1].

They agree the effects fade without follow-through. Ketamine relief wears off in about three days to a week unless sessions are stacked [1]; relapse after psilocybin in treatment-resistant depression is common by three months [2]. MDMA looks different: Huberman notes in conversation with Carhart-Harris that some MDMA remission rates for trauma lasted years, "which is different than what you're describing for psilocybin where people might need ongoing dosing," and Carhart-Harris agrees [2]. The sources do not explain this difference, though MDMA protocols build in three integration sessions [4] and MDMA rewards social connection even after the drug wears off [4].

They agree microdosing is unproven. Huberman's clinician colleagues know of zero published clinical evidence that microdosing ketamine helps depression [1]. Carhart-Harris describes a self-blinded LSD study in which placebo matched microdosing [2]: "Science is not about what you want to believe" [2].

They disagree, in emphasis, about the role of the experience itself. Huberman, drawing on the naltrexone study, argues the vivid experience may not be what heals: patients still felt ketamine's euphoria and dissociation but lost the antidepressant effect [1]. Carhart-Harris argues the reverse for psilocybin: the strength of certain experiences reliably predicts outcomes, and he doubts that a trip-free 2A drug would work the same way [2]. Huberman's own psilocybin episode sides partly with Carhart-Harris: the strongest predictor of benefit in one trial was "oceanic boundlessness," and responders and non-responders did not differ much in hallucinations, so imagery alone did not bring relief [3]. The paper concludes that "it seems vital that appropriate consideration is paid to the importance of promoting a certain kind of experience" [3]. Each side has a reason. Huberman's evidence is a pharmacological dissociation in ketamine, where the felt state and the benefit came apart [1]. Carhart-Harris's evidence is correlational data across psilocybin trials plus the expectancy finding [2]. Huberman himself reconciles them with the wavefront idea: the experience sets off several processes with different time courses, so it is not either-or [1]. Both positions share the insight's point: whatever the experience does, lasting benefit depends on processes that unfold over days, weeks and months after it.

They differ on how much of the brain changes, and where. Psilocybin increases lasting lateral connectivity [3][2][5]; MDMA does not seem to, instead weakening amygdala-insula coupling and lowering threat detection [4]. Ketamine's changes center on mood and reward circuits, the habenula and frontal cortex [1]. So "plasticity" is not one thing across the three drugs.

Why It Works

The sources give a layered set of mechanisms, all pointing to drugs as initiators of slow, experience-dependent change.

Ketamine: disinhibition, burst firing, BDNF. By blocking NMDA receptors on inhibitory neurons, ketamine lifts the brake on excitatory neurons in mood circuits, which fire in bursts ideal for plasticity; burst firing releases BDNF, which inserts new receptors and grows new branches [1]. Genetic evidence (BDNF knockout mice, people with poorly functioning BDNF) supports BDNF's necessity [1]. An opioid pathway runs in parallel, without which the antidepressant effect disappears [1]. In circuits, ketamine appears to weaken the habenula's inhibition of the reward pathway and strengthen connections between reward areas and the frontal cortex [1]. Huberman counts at least two and probably three mechanisms: immediate relief tied to the dissociative state, a second process over days and weeks, and long-lasting circuit rewiring [1].

Psilocybin: 2A activation, lateral connectivity, spine growth. Activating serotonin 2A receptors on apical dendrites increases lateral communication and broadens thalamic gating [3]. Connectivity and reduced modularity persist for at least three weeks and correlate with symptom improvement [2]. Dendritic spines grow and persist in mouse frontal cortex [3], and white-matter tracts to the prefrontal cortex may strengthen after one high dose [2].

MDMA: reward plus pro-social serotonin, lower threat. Dopamine rewards the experience while serotonin at 1B receptors in the nucleus accumbens drives the desire to connect, making connection rewarding even after the drug wears off [4]. Reduced amygdala activity and weaker amygdala-insula connectivity, scaling with symptom relief, suggest an opening for revisiting trauma without the usual threat response [4].

Why effects need behavior. Huberman's NMDA teaching explains why: plasticity is driven by unusual, repeated activity, as with a new finger sequence practiced for an hour, and he compares it to muscle hypertrophy, where overload plus rest leads to lasting strength [1]. The circuits ketamine opens are designed to respond to thinking and behavior, and the drug only biases which circuits get engaged [1]. Psilocybin's boulder rolls wherever the conscious mind pushes it [3]. The Sydney talk explains the practical advantage: under these drugs people can feel the full emotional force of an experience while reflecting on it with a guide [5].

Why drugs over electrodes. Plasticity at the level that matters means changing roughly a trillion synapses across the whole brain; a drug diffuses everywhere, while electrodes reach only a small surface region [6].

Where It Applies, and Where It Doesn't

Applies: clinical conditions with human support. The evidence covers ketamine for depression, suicidality and PTSD, especially treatment-resistant cases [1]; psilocybin for treatment-resistant depression, with the strongest evidence for cancer-related depression and anxiety and moderate evidence for alcohol and tobacco addiction [3]; and MDMA-assisted therapy for PTSD, including the hard-to-treat dissociative form, with many participants' substance use problems resolving too [4]. Carhart-Harris's team is testing psilocybin in anorexia and fibromyalgia, with early but unpublished results [2].

Doesn't apply: recreational or unstructured use. Carhart-Harris calls clinical sessions "a world away" from a rave [2]; Huberman contrasts eyes-closed sessions with heading to the woods or the beach [3]. He warns of a growing crossover where people obtain ketamine legally but take it at home, under conditions very different from research [1]. Hot, crowded dance settings raise MDMA's neurotoxic risk [4]. Street MDMA and psychedelics can be contaminated with fentanyl [2][4].

Doesn't apply: people for whom plasticity is risky. People with psychosis or a predisposition to it, including a first-degree relative with schizophrenia or bipolar disorder, are typically excluded from psilocybin studies, as are people under about 25 and pregnant or breastfeeding women [3]. Huberman says "being an adolescent a kid or a teen is a psychedelic experience" and does not recommend psychedelics for young people [5]. Ketamine can trigger seizures in seizure-prone people, and combining it with alcohol or barbiturates is dangerous [1]. MDMA raises heart rate, blood pressure and body temperature [4], and a physician will likely be needed nearby because of its cardiac risks [2].

Doesn't apply: drug-only thinking. SSRIs taken before MDMA block its pro-social effects [4], and no one should stop antidepressants on their own; any change should go through a physician and psychiatrist [3]. Microdosing lacks evidence for either ketamine or LSD [1][2]. And plasticity is not automatically good: brain injury and methamphetamine also rewire the brain [3].

Limits on the evidence. Several key findings are small, unpublished or in animals: the first-time-use imaging study [2], the anorexia and fibromyalgia trials [2], and the dendritic spine work at doses above human ones [3]. Legal status also limits access: psilocybin and MDMA were Schedule I at the time of recording [3][4], and trial participants who relapse cannot get more sessions once a trial ends [2]. MacDougall's view about drugs over electrodes is an opinion from a surgeon, not a trial result [6].

Anyone considering these treatments should do so only with qualified clinicians, and should talk to their own doctor or psychiatrist before changing any medication.

What To Do With It

1. Treat the drug session as the start of the work, not the work. Huberman's wedge image [3] and Carhart-Harris's "after the ecstasy, the laundry" [2] say the same thing: plan what you will do in the days and weeks afterward before the session happens.

2. Stack antidepressive behaviors on top of any ketamine treatment. Huberman lists morning sunlight, regular quality sleep, good nutrition and social engagement, plus stimulating work and care for your body, as the behaviors that reinforce ketamine's circuit changes [1]. Avoid bright light between roughly 11 p.m. and 4 a.m., which activates the habenula and promotes depressive symptoms [1].

3. Expect ketamine to need repeated, clinically spaced sessions. Single doses fade in about three days to a week; regimens such as twice a week for three weeks produced relief lasting weeks or months [1]. Don't count on microdosing: there is no published clinical evidence it helps depression [1].

4. Use the clinical setting, not a recreational one. Eyes closed or an eye mask, carefully arced music, one or two trained sober people, and a physically safe room are the standard for psilocybin sessions [2][3]. Never use street-sourced drugs, which may contain fentanyl [2][4].

5. Build trust with your therapists before dosing, and practice letting go. Trust rated on the morning of dosing predicts both the experience and outcomes weeks or months later [2]. Johnson's lab teaches the physiological sigh so participants can calm themselves in real time and keep moving through anxiety [3].

6. Bring your therapy questions into the experience, and take notes afterward. Huberman describes the value as feeling an issue fully while reflecting on it with a guide, and taking notes that "lead to specific actionable outcomes" [5]. For MDMA, the MAPS model of three preparation and three integration sessions around each round of dosing shows the structure [4].

7. Turn integration into a lasting practice. Since clinics cannot support patients forever, Carhart-Harris suggests integration becomes a practice like meditation, learning to "sit with rather than sit on" difficult feelings [2].

8. Check the exclusions first. A personal or family history of psychosis, schizophrenia or bipolar disorder, being under about 25, pregnancy, seizure risk, heart problems, or current SSRI use all matter [1][3][4]. Never stop an antidepressant on your own [3].

9. Mind the dose route with ketamine. Oral ketamine delivers about 25% to the bloodstream and a sublingual troche about 35%, so equivalent doses differ greatly from injection; misjudging can push someone into a K-hole, and no one should drive or be alone after at-home use [1].

10. Keep realistic expectations about relapse. In treatment-resistant depression, relapse after psilocybin by three months is common [2], so plan for continued support, and remember Huberman's closing line: "better living through chemistry still requires better living" [1].

Sources

1. Ketamine Benefits and Risks for Depression, PTSD & Neuroplasticity | Huberman Lab Podcast · Huberman Lab
2. Dr Robin Carhart Harris The Science Of Psychedelics For Mental Health · Huberman Lab
3. How Psilocybin Can Rewire Our Brain, Its Therapeutic Benefits & Its Risks · Huberman Lab
4. The Science of MDMA & Its Therapeutic Uses, Benefits & Risks · Huberman Lab
5. LIVE EVENT Q&A: Dr. Andrew Huberman at the Sydney Opera House · Huberman Lab
6. Dr Matthew Macdougall Neuralink Technologies To Enhance Human Brains · Huberman Lab